Storia in 8 fonti

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

gizmodo.com2 g fa

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium Therapeutics annuncia Phase III di DT120 (LSD proprietaria): singola dose raggiunge 35% remissione versus 7% placebo nella depressione clinica. Per manager tech il segnale è una terapia single-dose disruptive rispetto ai trattamenti cronici attuali, con impatto potenziale su employee wellness e healthcare spending aziendale.

Leggi questa versione → originale

endpoints.news3 g fa

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in depression symptoms.

Leggi questa versione → originale

investors.com2 g fa

Biotech Goes Sky-High After LSD Drug Treats Depression

One analyst called this a "best-case" scenario for the company's experimental depression treatment.

Leggi questa versione → originale

statnews.com3 g fa

Definium LSD therapy helped patients with major depression in late-stage trial

Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.

Leggi questa versione → originale

benzinga.com2 g fa

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder — with the…

Leggi questa versione → originale

zerohedge.com3 g fa

Psychedelic Stocks Could Explode Higher

Definium's DT120 met Phase 3 for LSD-based depression therapy, driving DFTX +200% YTD with single-dose efficacy versus SSRIs. Policy-driven FDA expedited pathway opens M&A consolidation window; psychedelic therapeutics signal broader deregulation trend in healthcare.

Leggi questa versione → originale

Timeline cronologica

lunedì 22 giugno 2026·zerohedge.com
Psychedelic Stocks Could Explode Higher
Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...
lunedì 22 giugno 2026·statnews.com
Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.
lunedì 22 giugno 2026·endpoints.news
Definium reports Phase 3 hit for LSD drug in severe form of depression
Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in depression symptoms.
lunedì 22 giugno 2026·benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…
lunedì 22 giugno 2026·investors.com
Biotech Goes Sky-High After LSD Drug Treats Depression
One analyst called this a "best-case" scenario for the company's experimental depression treatment.
lunedì 22 giugno 2026·zerohedge.com
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.
lunedì 22 giugno 2026·morningstar.com
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. Announces Proposed Public Offering
lunedì 22 giugno 2026·gizmodo.com
LSD Just Passed Its Biggest Test Yet for Treating Depression
People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, the company announced Monday.
martedì 23 giugno 2026·benzinga.com
What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.
mercoledì 24 giugno 2026·morningstar.com
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
mercoledì 24 giugno 2026·medpagetoday.com
LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
News and commentary from the psychiatry world

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium reports Phase 3 hit for LSD drug in severe form of depression

Biotech Goes Sky-High After LSD Drug Treats Depression

Definium LSD therapy helped patients with major depression in late-stage trial

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Psychedelic Stocks Could Explode Higher

Timeline cronologica

Psychedelic Stocks Could Explode Higher

Definium LSD therapy helped patients with major depression in late-stage trial

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Biotech Goes Sky-High After LSD Drug Treats Depression